Evidence map›Paper›PMID 24386459›Full record

Trial reportPloS one2013

Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.

Gunjan Gakhar, Vicente N Navarro, Madelyn Jurish, Guang Yu Lee, Scott T Tagawa, Naveed H Akhtar, Marco Seandel, Yue Geng, He Liu, Neil H Bander and 4 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. I-branched carbohydrates as emerging effectors of malignant progression.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Gunjan GakharDeparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America.
Vicente N NavarroDepartment of Urology, Weill Cornell Medical College, New York, New York, United States of America.
Madelyn JurishDeparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America.
Guang Yu LeeDeparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America.
Scott T TagawaDeparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America ; Department of Urology, Weill Cornell Medical College, New York, New York, United States of America ; Weill Cornell Cancer Center, Weill Cornell Medical College, New York, New York, United States of America.
Naveed H AkhtarDeparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America.
Marco SeandelDepartment of Surgery, Weill Cornell Medical College, New York, New York, United States of America.
Yue GengDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, United States of America.
He LiuDepartment of Urology, Weill Cornell Medical College, New York, New York, United States of America.
Neil H BanderDepartment of Urology, Weill Cornell Medical College, New York, New York, United States of America ; Weill Cornell Cancer Center, Weill Cornell Medical College, New York, New York, United States of America.
Paraskevi GiannakakouDeparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America ; Weill Cornell Cancer Center, Weill Cornell Medical College, New York, New York, United States of America.
Paul J ChristosDivision of Biostatistics and Epidemiology, Department of Public Health, Weill Cornell Medical College, New York, New York, United States of America.
Michael R KingDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, United States of America.
David M NanusDeparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America ; Department of Urology, Weill Cornell Medical College, New York, New York, United States of America ; Weill Cornell Cancer Center, Weill Cornell Medical College, New York, New York, United States of America.
Cornell University · US

Funding

Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
TRANS-NETWORK PROJECTSU54CA143876 · NCI · CORNELL UNIVERSITY · PI SHULER, MICHAEL L · 2009 to 2014
$12.6M
Microtubule dependent AR signaling predicts taxane sensitivityR01CA137020 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GIANNAKAKOU, PARASKEVI · 2009 to 2013
$1.7M
NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1-TR000457-06NCI NIH HHS R01 CA137020NCI NIH HHS R01CA137020-01NCI NIH HHS U54 CA143876NCI NIH HHS U54CA143876
6 · The paper itself

Abstract

Hematogenous metastasis accounts for the majority of cancer-related deaths, yet the mechanism remains unclear. Circulating tumor cells (CTCs) in blood may employ different pathways to cross blood endothelial barrier and establish a metastatic niche. Several studies provide evidence that prostate cancer (PCa) cell tethering and rolling on microvascular endothelium via E-selectin/E-selectin ligand interactions under shear flow theoretically promote extravasation and contribute to the development of metastases. However, it is unknown if CTCs from PCa patients interact with E-selectin expressed on endothelium, initiating a route for tumor metastases. Here we report that CTCs derived from PCa patients showed interactions with E-selectin and E-selectin expressing endothelial cells. To examine E-selectin-mediated interactions of PCa cell lines and CTCs derived from metastatic PCa patients, we used fluorescently-labeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591-488 which is internalized following cell-surface binding. We employed a microscale flow device consisting of E-selectin-coated microtubes and human umbilical vein endothelial cells (HUVECs) on parallel-plate flow chamber simulating vascular endothelium. We observed that J591-488 did not significantly alter the rolling behavior in PCa cells at shear stresses below 3 dyn/cm(2). CTCs obtained from 31 PCa patient samples showed that CTCs tether and stably interact with E-selectin and E-selectin expressing HUVECs at physiological shear stress. Interestingly, samples collected during disease progression demonstrated significantly more CTC/E-selectin interactions than samples during times of therapeutic response (p=0.016). Analysis of the expression of sialyl Lewis X (sLe(x)) in patient samples showed that a small subset comprising 1.9-18.8% of CTCs possess high sLe(x) expression. Furthermore, E-selectin-mediated interactions between prostate CTCs and HUVECs were diminished in the presence of anti-E-selectin neutralizing antibody. CTC-Endothelial interactions provide a novel insight into potential adhesive mechanisms of prostate CTCs as a means to initiate metastasis.

Indexed as

Stress, PhysiologicalBlood Flow VelocityCell LineE-SelectinHumansHuman Umbilical Vein Endothelial CellsMaleNeoplasm MetastasisNeoplasm ProteinsNeoplastic Cells, CirculatingProstatic NeoplasmsE-SelectinNeoplasm Proteins

Identifiers

PMID24386459
PMCPMC3874033
OpenAlexW2093986530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.